CYCL Quote, Financials, Valuation and Earnings

dMY Squared Technology Group has a net margin of -- compared to Cycclone's net margin of --. Cycclone's return on equity of -- beat dMY Squared Technology Group's return on equity of --.

Cycclone has a consensus price target of --, signalling downside risk potential of --. On the other hand dMY Squared Technology Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Cycclone has higher upside potential than dMY Squared Technology Group, analysts believe Cycclone is more attractive than dMY Squared Technology Group.

Cycclone has a beta of 2.065, which suggesting that the stock is 106.461% more volatile than S&P 500. In comparison dMY Squared Technology Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cycclone has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. dMY Squared Technology Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cycclone pays -- of its earnings as a dividend. dMY Squared Technology Group pays out -- of its earnings as a dividend.

Cycclone quarterly revenues are --, which are smaller than dMY Squared Technology Group quarterly revenues of --. Cycclone's net income of -- is lower than dMY Squared Technology Group's net income of -$4.6M. Notably, Cycclone's price-to-earnings ratio is -- while dMY Squared Technology Group's PE ratio is 59.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cycclone is -- versus -- for dMY Squared Technology Group. Usually stocks with elevated PS ratios are considered overvalued.

Future Health ESG has a net margin of -- compared to Cycclone's net margin of --. Cycclone's return on equity of -- beat Future Health ESG's return on equity of --.

Cycclone has a consensus price target of --, signalling downside risk potential of --. On the other hand Future Health ESG has an analysts' consensus of -- which suggests that it could fall by --. Given that Cycclone has higher upside potential than Future Health ESG, analysts believe Cycclone is more attractive than Future Health ESG.

Cycclone has a beta of 2.065, which suggesting that the stock is 106.461% more volatile than S&P 500. In comparison Future Health ESG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cycclone has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Future Health ESG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cycclone pays -- of its earnings as a dividend. Future Health ESG pays out -- of its earnings as a dividend.

Cycclone quarterly revenues are --, which are smaller than Future Health ESG quarterly revenues of --. Cycclone's net income of -- is lower than Future Health ESG's net income of --. Notably, Cycclone's price-to-earnings ratio is -- while Future Health ESG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cycclone is -- versus -- for Future Health ESG. Usually stocks with elevated PS ratios are considered overvalued.

Graf Global has a net margin of -- compared to Cycclone's net margin of --. Cycclone's return on equity of -- beat Graf Global's return on equity of --.

Cycclone has a consensus price target of --, signalling downside risk potential of --. On the other hand Graf Global has an analysts' consensus of -- which suggests that it could fall by --. Given that Cycclone has higher upside potential than Graf Global, analysts believe Cycclone is more attractive than Graf Global.

Cycclone has a beta of 2.065, which suggesting that the stock is 106.461% more volatile than S&P 500. In comparison Graf Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cycclone has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Graf Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cycclone pays -- of its earnings as a dividend. Graf Global pays out -- of its earnings as a dividend.

Cycclone quarterly revenues are --, which are smaller than Graf Global quarterly revenues of --. Cycclone's net income of -- is lower than Graf Global's net income of $2.2M. Notably, Cycclone's price-to-earnings ratio is -- while Graf Global's PE ratio is 39.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cycclone is -- versus -- for Graf Global. Usually stocks with elevated PS ratios are considered overvalued.

Legato Merger Corp III has a net margin of -- compared to Cycclone's net margin of --. Cycclone's return on equity of -- beat Legato Merger Corp III's return on equity of --.

Cycclone has a consensus price target of --, signalling downside risk potential of --. On the other hand Legato Merger Corp III has an analysts' consensus of -- which suggests that it could fall by --. Given that Cycclone has higher upside potential than Legato Merger Corp III, analysts believe Cycclone is more attractive than Legato Merger Corp III.

Cycclone has a beta of 2.065, which suggesting that the stock is 106.461% more volatile than S&P 500. In comparison Legato Merger Corp III has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cycclone has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legato Merger Corp III offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cycclone pays -- of its earnings as a dividend. Legato Merger Corp III pays out -- of its earnings as a dividend.

Cycclone quarterly revenues are --, which are smaller than Legato Merger Corp III quarterly revenues of --. Cycclone's net income of -- is lower than Legato Merger Corp III's net income of $2.1M. Notably, Cycclone's price-to-earnings ratio is -- while Legato Merger Corp III's PE ratio is 29.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cycclone is -- versus -- for Legato Merger Corp III. Usually stocks with elevated PS ratios are considered overvalued.